leukocytes

[Nature Reviews Nephrology] Comprehensive studies are needed to investigate the relationships between segment-specific changes in the microvasculature and kidney function loss in sepsis-AKI.

[Nature Communications] Investigators reported that TET2 mutations are associated with DNA hypermethylation at enhancer sites in whole blood in clonal hematopoiesis of indeterminate potential and in both granulocytes and mononuclear cells in clonal cytopenia of undetermined significance.

[Molecular Therapy-Oncolytics] CAR-engineered natural killer (NK)-92 cells have demonstrated robust antitumor activity in in vitro and in vivo preclinical studies, propelling the clinical development of CAR NK-92 cells.

[European Respiratory Journal] Scientists comparatively assessed how the inflammatory environment present in acute respiratory distress syndrome lungs versus the lung environment present in healthy volunteers alters MSC behavior.

[Immune-Onc Therapeutics, Inc.] Immune-Onc Therapeutics, Inc. announced that the first patient has been dosed in the company’s first-in-human clinical trial of IO-108, a novel antagonist antibody targeting the myeloid checkpoint Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) for the treatment of solid tumors.

[Nanoscale] The immunosuppressive tumor microenvironment has become a formidable obstacle to the treatment of tumors using adoptive T cell therapy, in particular solid tumors. Effector OT-1 CD8+T cells conjugated with liposomal immune regulators were developed to address this issue.